Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study
| Autor: | Marta A. Crispens, Patricia S. Braly, Maurie Markman, A. Lisyanskaya, D. Doering, B. Michiels, D.S. McMeekin, E. Bayever, Amit M. Oza |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
medicine.medical_specialty Nausea medicine.medical_treatment Population Phases of clinical research Dioxoles Gastroenterology Disease-Free Survival Young Adult Internal medicine Multicenter trial Tetrahydroisoquinolines medicine Humans Progression-free survival education Infusions Intravenous Antineoplastic Agents Alkylating Trabectedin Aged Aged 80 and over education.field_of_study Chemotherapy business.industry Endometrial cancer Obstetrics and Gynecology Middle Aged medicine.disease Surgery Endometrial Neoplasms Oncology Female medicine.symptom Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Gynecologic oncology. 114(2) |
| ISSN: | 1095-6859 |
| Popis: | Objective To assess the efficacy and safety of single-agent trabectedin in women with persistent or recurrent endometrial cancer. Methods In this open-label, phase II multicenter trial, women with persistent or recurrent endometrial carcinoma were administered trabectedin as a 3-hour intravenous infusion every 21 days at a starting dose of 1.3 mg/m 2 with dexamethasone pretreatment. Clinical objective response was the primary efficacy endpoint. Secondary endpoints were time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety. Results The median age of the 50 women entering the study was 63 years (range, 22–87), with all having history of prior chemotherapy (92% combination regimens) and the majority having undergone surgery (92%) or radiation therapy (68%). Patients received trabectedin for a median duration of 6.8 weeks (range, 3–20). A median of 2 cycles (range, 1–6) was administered, with a median dose intensity of 0.4 mg/m 2 per week (range, 0.27–0.43) and a median relative dose intensity of 92% (range, 61.5–100.2%). One patient exhibited a complete response for an objective response rate of 2.2% (95% confidence interval [CI]: 0.1%, 11.5%). Median TTP and PFS were both 1.8 months (95% CI: 1.4, 2.9), and median OS was 6.7 months (95% CI: 5.2, 13.9). Most frequent adverse events were nausea (62%), asthenia (50%), vomiting (42%), and increased alanine aminotransferase (40%). Conclusion Single-agent trabectedin displayed minimal antitumor activity in this pretreated population of women with persistent or recurrent endometrial cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect